High-dose D-serine improves neuropsychiatric symptoms in patients with schizophrenia.
Although most antipsychotic drugs are based on the dopamine model of schizophrenia, phencyclidine (which induces psychotic symptoms) modulates N-methyl-d-aspartate (NMDA) receptors. In some studies, an agonist at the NMDA site, d-serine, has demonstrated positive results at 30 mg/kg/day in patients with schizophrenia. To explore the relative safety and efficacy of various d-serine doses, researchers examined the effects of 30 mg/kg/day, 60 mg/kg/day, and 120 mg/kg/day in 42 patients with schizophrenia or schizoaffective disorder who were stabilized on antipsychotics (>450 mg/day of chlorpromazine equivalents). The senior author has intellectual property rights to this therapeutic approach.
Patients were in their early 40s, were predominately…
Reviewing Author
DisclosuresRoyaltiesTextbook of Traumatic Brain Injury, 2nd and 3rd editions
Editorial BoardsUpToDate; Journal of Neuropsychiatry and Clinical Neuroscience
Leadership Positions in Professional SocietiesNorth American Brain Injury Association (Board Member); National Institute on Disability, Independent Living, and Rehabilitation Research (Chair of Data Monitoring Safety Board for study of donepezil on cognition after traumatic brain injury)
DisclosuresRoyaltiesTextbook of Traumatic Brain Injury, 2nd and 3rd editions
Editorial BoardsUpToDate; Journal of Neuropsychiatry and Clinical Neuroscience
Leadership Positions in Professional SocietiesNorth American Brain Injury Association (Board Member); National Institute on Disability, Independent Living, and Rehabilitation Research (Chair of Data Monitoring Safety Board for study of donepezil on cognition after traumatic brain injury)